Business Wire

THALES/NEURAL-LABS

Share
Thales Partners with Neural Labs to Support AI-Powered Smart Cities

Thales, a global leader in Software Monetization and Licensing, has expanded its partnership with Neural Labs, a company which provides video analysis for Smart Cities and AI-based Intelligent Transportation Systems (ITS), to enable secure, efficient, and practical solutions for vehicle access control and logistical planning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313492188/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

© Thales

Thales’s Sentinel platform provides services for software licensing, entitlement management, delivery, and protection – helping Neural Labs to quickly and efficiently automate the creation and issuance of licenses. As a result, Neural Labs was able to reduce costs and focus more on its customers, as well as the value of its software against competitors.

The relationship between Thales and Neural Labs initially started over two decades ago when Neural Labs selected Sentinel for software protection. Since then, the company has moved into a new era of digital transformation and adopted Thales Sentinel Cloud Licensing to manage its SaaS offering.

With this latest licensing iteration, Neural Labs can maximise SaaS capabilities to deploy and update licenses from any location for their entire product portfolio and growing sales teams. This partnership expansion is therefore crucial for the organisation to achieve its growth ambitions in an increasingly connected world.

Over the last three years, Neural Labs increased its revenue by nearly 25%, with Thales Sentinel playing its part by helping to reduce revenue leakage from unauthorized software use.

“We always knew that we needed to protect our software and futureproof our business. Thales has been there with us since the very beginning to help us to avoid software piracy and make the most of every market opportunity. Now, we’re working with the team even more closely to prepare our software so that 100% will be offered on the cloud. The expansion of this partnership will help us to scale with the flexible and practical solutions, and our longstanding relationship means we can move forward with full trust.” Elias Varcarcel, CEO, Neural Labs

“For over 20 years, our team has provided the technical support to help Neural Labs on its mission to make cities, towns and the road network safer, smarter and more efficient. We’re incredibly proud that Neural Lab’s confidence in our platform and services has allowed them to grow exponentially. We’re now looking ahead to the next stage – full digital transformation backed by flexible and scalable solutions.” Damien Bullot, Vice President, Software Monetization, Thales

About Neural Labs

Neural Labs has more than 20 years of experience in the development of specialized software based on reading license plates and video analytics to revolutionize various sectors such as Smart Cities, Mobility, Security, Intelligent Transport Systems (ITS), vehicle traffic management, infractions control, logistics, and vehicular access. This remarkable array of capabilities stands as a testament to Neural Labs' substantial commitment to Research and Development.

The solutions crafted by Neural Labs go above and beyond, demonstrating excellence in reading and identifying vehicle license plates (ANPR or LPR) and ISO6346 codes of transport containers (ACCR).

Neural Labs is dedicated to designing solutions that simplify the lives of its clients, transforming their environments into safer and more efficient spaces.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested

PLEASE VISIT
Thales Group
Security
@Thalesgroup

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313492188/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye